During the American Society of Clinical Oncology (ASCO) meeting earlier this year, a leading pharmaceutical company announced positive results for one of its drugs. For the first time in 10 years, a drug used to battle a recurrent cancer had been found to prolong life, in this case by more than a month. However, by the conference’s conclusion, news media reports focused on its cost.

Many evidence-based treatment options with similar outcomes have vastly different financial implications. Two years ago, Memorial Sloan Kettering refused to include a new, more expensive cancer drug on its formulary, saying it was no more effective than a less expensive drug currently in use. “When choosing treatments for a patient, we have to consider the financial strains,” wrote three of the hospital’s physicians in a New York Times op-ed.

In another example, the six-month cost for first-line treatment of metastatic colorectal cancer (CRC) and gastric cancer varies widely despite the clinical effectiveness being similar. (Journal of the National Comprehensive Cancer Network 2012;10:1037-1042).

Read More

Thank you for your interest in our content. Registering allows you to access a wide range of informative articles, briefs, and whitepapers throughout the site.

Privacy is important. We do not share registrant information with anyone outside of Numerof & Associates. For details, please see our Privacy Policy. Subscribers to our mailings can unsubscribe instantly at any time.